 |
|
Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer–Norfolk CohortDoes Adding Glycated Hemoglobin Improve the Prediction of Coronary Heart Disease Events?
Rebecca K. Simmons, PhD;
Stephen Sharp, MSc;
S. Matthijs Boekholdt, MD, PhD;
Lincoln A. Sargeant, PhD;
Kay-Tee Khaw, PhD;
Nicholas J. Wareham, PhD;
Simon J. Griffin, DM
Arch Intern Med. 2008;168(11):1209-1216.
Background There is a continuous relationship between glycated hemoglobin (HbA1c) and coronary heart disease (CHD) risk, even below diagnostic thresholds for diabetes mellitus.
Methods To evaluate the Framingham risk score in a UK population-based prospective cohort (European Prospective Investigation of Cancer [EPIC]–Norfolk) and to assess whether adding HbA1c improves the prediction of CHD. Participants aged 40 to 79 years were recruited from UK general practices, attended a health check, and were followed up for CHD events and death. The Framingham risk score was computed for 10 295 individuals with data on age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diabetes mellitus, and smoking status. We developed a Cox proportional hazards regression model with the original Framingham covariates and then added HbA1c to determine whether this improved the prediction of CHD. Model discrimination was compared by using area under the receiver operating characteristic curves (AUROCs), and the correctness of reclassification was determined by calculating the net reclassification improvement and the integrated discrimination improvement. The main outcome measures were CHD-related hospital admission and death.
Results A total of 430 men and 250 women developed CHD during 8.5 years of follow-up. The AUROC for the original Framingham risk score was 0.71. Using the Framingham variables with coefficients fitted from the EPIC-Norfolk data, the AUROC was 0.72 for men and 0.80 for women, compared with 0.73 and 0.80, respectively, in a score including HbA1c. This difference was significant for men only (P = .005). The net reclassification improvement was 3.4% (P = .06) in men and –2.2% (P = .27) in women.
Conclusions The Framingham risk score predicts CHD in this cohort. The addition of HbA1c made a small but statistically significant improvement to discrimination in men but not in women, without significant improvement in reclassification of risk category.
Author Affiliations: MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, England (Drs Simmons, Sargeant, Wareham, and Griffin and Mr Sharp); Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands (Dr Boekholdt); and Department of Clinical Gerontology, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge (Dr Khaw).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer–Norfolk Cohort—Invited Commentary
Michael J. Pencina and Ralph B. D’Agostino
Arch Intern Med. 2008;168(11):1216-1218.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Use of reclassification for assessment of improved prediction: an empirical evaluation
Tzoulaki et al.
Int J Epidemiol 2011;40:1094-1105.
ABSTRACT
| FULL TEXT
Risk Assessment Tools for Identifying Individuals at Risk of Developing Type 2 Diabetes
Buijsse et al.
Epidemiol Rev 2011;33:46-62.
ABSTRACT
| FULL TEXT
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Writing Committee Members et al.
Circulation 2010;122:e584-e636.
FULL TEXT
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance
Greenland et al.
J Am Coll Cardiol 2010;56:e50-e103.
FULL TEXT
Coronary Risk Stratification, Discrimination, and Reclassification Improvement Based on Quantification of Subclinical Coronary Atherosclerosis: The Heinz Nixdorf Recall Study
Erbel et al.
J Am Coll Cardiol 2010;56:1397-1406.
ABSTRACT
| FULL TEXT
Improvement of Risk Prediction by Genomic Profiling: Reclassification Measures Versus the Area Under the Receiver Operating Characteristic Curve
Mihaescu et al.
Am J Epidemiol 2010;172:353-361.
ABSTRACT
| FULL TEXT
Cardiovascular Risk-Estimation Systems in Primary Prevention: Do They Differ? Do They Make a Difference? Can We See the Future?
Cooney et al.
Circulation 2010;122:300-310.
FULL TEXT
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up
Preiss et al.
Eur Heart J 2010;31:1230-1236.
ABSTRACT
| FULL TEXT
Coronary Artery Calcium Score and Risk Classification for Coronary Heart Disease Prediction
Polonsky et al.
JAMA 2010;303:1610-1616.
ABSTRACT
| FULL TEXT
Barriers to Routine Risk-Score Use for Healthy Primary Care Patients: Survey and Qualitative Study
Muller-Riemenschneider et al.
Arch Intern Med 2010;170:719-724.
ABSTRACT
| FULL TEXT
Systematic Review of Guidelines on Cardiovascular Risk Assessment: Which Recommendations Should Clinicians Follow for a Cardiovascular Health Check?
Ferket et al.
Arch Intern Med 2010;170:27-40.
ABSTRACT
| FULL TEXT
Assessment of Claims of Improved Prediction Beyond the Framingham Risk Score
Tzoulaki et al.
JAMA 2009;302:2345-2352.
ABSTRACT
| FULL TEXT
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study
Rana et al.
Heart 2009;95:1682-1687.
ABSTRACT
| FULL TEXT
Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk: A Review for Clinicians
Cooney et al.
J Am Coll Cardiol 2009;54:1209-1227.
ABSTRACT
| FULL TEXT
Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer-Norfolk Cohort--Invited Commentary
Pencina and D'Agostino
Arch Intern Med 2008;168:1216-1218.
FULL TEXT
|
